[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[2]
|
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O., Abdelalim, A., Abdoli, A., Abdollahpour, I., Abdulle, A.S.M., Abebe, N.D., Abraha, H.N., Abu-Raddad, L.J., Abualhasan, A., Adedeji, I.A., Advani, S.M., Afarideh, M., Afshari, M., Aghaali, M. and Murray, C.J.L. (2019) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology, 5, 1749-1768.
|
[3]
|
El-Serag, H.B. (2012) Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 142, 1264-1273.e1. https://doi.org/10.1053/j.gastro.2011.12.061
|
[4]
|
Younossi, Z.M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S. and Beckerman, R. (2016) The Economic and Clinical Burden of Nonalcoholic Fatty Liver Disease in the United States and Europe. Hepatology (Baltimore, Md.), 64, 1577-1586. https://doi.org/10.1002/hep.28785
|
[5]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology (Baltimore, Md.), 64, 73-84. https://doi.org/10.1002/hep.28431
|
[6]
|
Hassan, M.M., Hwang, L.Y., Hatten, C.J., Swaim, M., Li, D., Abbruzzese, J.L., Beasley, P. and Patt, Y.Z. (2002) Risk Factors for Hepatocellular Carcinoma: Synergism of Alcohol with Viral Hepatitis and Diabetes Mellitus. Hepatology (Baltimore, Md.), 36, 1206-1213. https://doi.org/10.1053/jhep.2002.36780
|
[7]
|
Ross, R.K., Yuan, J.M., Yu, M.C., Wogan, G.N., Qian, G.S., Tu, J.T., Groopman, J.D., Gao, Y.T. and Henderson, B.E. (1992) Urinary Aflatoxin Biomarkers and Risk of Hepatocellular Carcinoma. The Lancet (London, England), 339, 943-946. https://doi.org/10.1016/0140-6736(92)91528-G
|
[8]
|
Ng, A.W.T., Poon, S.L., Huang, M.N., Lim, J.Q., Boot, A., Yu, W., Suzuki, Y., Thangaraju, S., Ng, C.C.Y., Tan, P., Pang, S.T., Huang, H.Y., Yu, M.C., Lee, P.H., Hsieh, S.Y., Chang, A.Y., Teh, B.T. and Rozen, S.G. (2017) Aristolochic Acids and Their Derivatives Are Widely Implicated in Liver Cancers in Taiwan and throughout Asia. Science Translational Medicine, 9, eaan6446. https://doi.org/10.1126/scitranslmed.aan6446
|
[9]
|
Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. The Lancet (London, England), 391, 1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2
|
[10]
|
Sheka, A.C., Adeyi, O., Thompson, J., Hameed, B., Crawford, P.A. and Ikramuddin, S. (2020) Nonalcoholic Steatohepatitis: A Review. JAMA, 323, 1175-1183. https://doi.org/10.1001/jama.2020.2298
|
[11]
|
Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C. and Williams, R. (1973) Transection of the Oesophagus for Bleeding Oesophageal Varices. The British Journal of Surgery, 60, 646-649. https://doi.org/10.1002/bjs.1800600817
|
[12]
|
Kamath, P.S., Kim, W.R. and Advanced Liver Disease Study Group (2007) The Model for End-Stage Liver Disease (MELD). Hepatology (Baltimore, Md.), 45, 797-805. https://doi.org/10.1002/hep.21563
|
[13]
|
Arroyo, V. and Colmenero, J. (2003) Ascites and Hepatorenal Syndrome in Cirrhosis: Pathophysiological Basis of Therapy and Current Management. Journal of Hepatology, 38, S69-S89. https://doi.org/10.1016/S0168-8278(03)00007-2
|
[14]
|
Fernández-Esparrach, G., Sánchez-Fueyo, A., Ginès, P., Uriz, J., Quintó, L., Ventura, P.J., Cárdenas, A., Guevara, M., Sort, P., Jiménez, W., Bataller, R., Arroyo, V. and Rodés, J. (2001) A Prognostic Model for Predicting Survival in Cirrhosis with Ascites. Journal of Hepatology, 34, 46-52. https://doi.org/10.1016/S0168-8278(00)00011-8
|
[15]
|
Biggins, S.W., Kim, W.R., Terrault, N.A., Saab, S., Balan, V., Schiano, T., Benson, J., Therneau, T., Kremers, W., Wiesner, R., Kamath, P. and Klintmalm, G. (2006) Evidence-Based Incorporation of Serum Sodium Concentration into MELD. Gastroenterology, 130, 1652-1660. https://doi.org/10.1053/j.gastro.2006.02.010
|
[16]
|
Luca, A., Angermayr, B., Bertolini, G., Koenig, F., Vizzini, G., Ploner, M., Peck-Radosavljevic, M., Gridelli, B. and Bosch, J. (2007) An Integrated MELD Model Including Serum Sodium and Age Improves the Prediction of Early Mortality in Patients with Cirrhosis. Liver Transplantation, 13, 1174-1180. https://doi.org/10.1002/lt.21197
|
[17]
|
Chen, K., Cao, X., Zheng, Y., Xu, M. and Peng, J. (2014) Comparative Study of the MELD-Na and Child-Turcotte-Pugh Scores as Short-Term Prognostic Indicators of Acute-on-Chronic Hepatitis B Liver Failure. Chinese Journal of Hepatology, 22, 801-805. (In Chinese) https://doi.org/10.3760/cma.j.issn.1007-3418.2014.11.001
|
[18]
|
Kim, K.M., Shim, S.G., Sinn, D.H., Song, J.E., Kim, B.S. and Kim, H.G. (2020) Child-Pugh, MELD, MELD-Na, and ALBI Scores: Which Liver Function Models Best Predicts Prognosis for HCC Patient with Ascites? Scandinavian Journal of Gastroenterology, 55, 951-957. https://doi.org/10.1080/00365521.2020.1788139
|
[19]
|
Huo, T.I., Lin, H.C., Hsia, C.Y., Huang, Y.H., Wu, J.C., Chiang, J.H., Chiou, Y.Y., Lui, W.Y., Lee, P.C. and Lee, S.D. (2008) The MELD-Na Is an Independent Short- and Long-Term Prognostic Predictor for Hepatocellular Carcinoma: A Prospective Survey. Digestive and Liver Disease, 40, 882-889. https://doi.org/10.1016/j.dld.2008.01.015
|
[20]
|
Ahmed, R., Santhanam, P. and Rayyan, Y. (2015) MELD-Na as a Prognostic Indicator of 30- and 90-Day Mortality in Patients with End-Stage Liver Disease after Creation of Transjugular Intrahepatic Portosystemic Shunt. European Journal of Gastroenterology & Hepatology, 27, 1226-1227. https://doi.org/10.1097/MEG.0000000000000412
|
[21]
|
Pozo-Laderas, J.C., Rodríguez-Perálvarez, M., Muñoz-Villanueva, M.C., Rivera-Espinar, F., Durban-García, I., Muñoz-Trujillo, J., Robles-Arista, J.C. and Briceño-Delgado, J. (2019) Pretransplant Predictors of Early Mortality in Adult Recipients of Liver Transplantation in the MELD-Na Era. Predictores Pretrasplante de Mortalidad Precoz en Receptores Adultos de Trasplante Hepático en la era MELD-Na. Medicina Intensiva, 43, 261-269. https://doi.org/10.1016/j.medin.2018.03.008
|
[22]
|
Wong, V.W., Chim, A.M., Wong, G.L., Sung, J.J. and Chan, H.L. (2007) Performance of the New MELD-Na Score in Predicting 3-Month and 1-Year Mortality in Chinese Patients with Chronic Hepatitis B. Liver Transplantation, 13, 1228-1235. https://doi.org/10.1002/lt.21222
|
[23]
|
Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., Yeo, W., Mo, F., Lai, P., Iñarrairaegui, M., Chan, S.L., Sangro, B., Miksad, R., Tada, T., Kumada, T. and Toyoda, H. (2015) Assessment of Liver Function in Patients with Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. Journal of Clinical Oncology, 33, 550-558. https://doi.org/10.1200/JCO.2014.57.9151
|
[24]
|
Wang, J., Zhang, Z., Yan, X., Li, M., Xia, J., Liu, Y., Chen, Y., Jia, B., Zhu, L., Zhu, C., Huang, R. and Wu, C. (2019) Albumin-Bilirubin (ALBI) as an Accurate and Simple Prognostic Score for Chronic Hepatitis B-Related Liver Cirrhosis. Digestive and Liver Disease, 51, 1172-1178. https://doi.org/10.1016/j.dld.2019.01.011
|
[25]
|
Chen, B. and Lin, S. (2017) Albumin-Bilirubin (ALBI) Score at Admission Predicts Possible Outcomes in Patients with Acute-on-Chronic Liver Failure. Medicine, 96, e7142. https://doi.org/10.1097/MD.0000000000007142
|
[26]
|
Fragaki, M., Sifaki-Pistolla, D., Orfanoudaki, E. and Kouroumalis, E. (2019) Comparative Evaluation of ALBI, MELD, and Child-Pugh Scores in Prognosis of Cirrhosis: Is ALBI the New Alternative? Annals of Gastroenterology, 32, 626-632. https://doi.org/10.20524/aog.2019.0417
|
[27]
|
Peng, Y., Qi, X., Tang, S., Deng, H., Li, J., Ning, Z., Dai, J., Hou, F., Zhao, J., Wang, R. and Guo, X. (2016) Child-Pugh, MELD, and ALBI Scores for Predicting the In-Hospital Mortality in Cirrhotic Patients with Acute-on-Chronic Liver Failure. Expert Review of Gastroenterology & Hepatology, 10, 971-980. https://doi.org/10.1080/17474124.2016.1177788
|
[28]
|
Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L., Lijmer, J.G., Moher, D., Rennie, D., de Vet, H.C., Kressel, H.Y., Rifai, N., Golub, R.M., Altman, D.G., Hooft, L., Korevaar, D.A., Cohen, J.F. and STARD Group (2015) STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Clinical Chemistry, 61, 1446-1452. https://doi.org/10.1373/clinchem.2015.246280
|
[29]
|
Llovet, J.M., Brú, C. and Bruix, J. (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Seminars in Liver Disease, 19, 329-338. https://doi.org/10.1055/s-2007-1007122
|
[30]
|
European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 56, 908-943. https://doi.org/10.1016/j.jhep.2011.12.001
|
[31]
|
Ji, J., Wang, H., Li, Y., Zheng, L., Yin, Y., Zou, Z., Zhou, F., Zhou, W., Shen, F. and Gao, C. (2016) Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLOS ONE, 11, e0153227. https://doi.org/10.1371/journal.pone.0153227
|
[32]
|
Ke, M.Y., Wu, X.N., Zhang, Y., Wang, S., Lv, Y. and Dong, J. (2019) Serum GP73 Predicts Posthepatectomy Outcomes in Patients with Hepatocellular Carcinoma. Journal of Translational Medicine, 17, Article No. 140. https://doi.org/10.1186/s12967-019-1889-0
|
[33]
|
Zhao, S., Wang, M., Yang, Z., Tan, K., Zheng, D., Du, X. and Liu, L. (2020) Comparison between Child-Pugh Score and Albumin-Bilirubin Grade in the Prognosis of Patients with HCC after Liver Resection Using Time-Dependent ROC. Annals of Translational Medicine, 8, 539. https://doi.org/10.21037/atm.2020.02.85
|
[34]
|
Zhao, S., Zhang, T., Li, H., Wang, M., Xu, K., Zheng, D., Du, X. and Liu, L. (2020) Comparison of Albumin-Bilirubin Grade versus Child-Pugh Score in Predicting the Outcome of Transarterial Chemoembolization for Hepatocellular Carcinoma Using Time-Dependent ROC. Annals of Translational Medicine, 8, 538. https://doi.org/10.21037/atm.2020.02.124
|
[35]
|
Hiraoka, A., Kumada, T., Kudo, M., Hirooka, M., Tsuji, K., Itobayashi, E., Kariyama, K., Ishikawa, T., Tajiri, K., Ochi, H., Tada, T., Toyoda, H., Nouso, K., Joko, K., Kawasaki, H., Hiasa, Y., Michitaka, K. and Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics) (2017) Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 6, 204-215. https://doi.org/10.1159/000452846
|
[36]
|
Schütte, K., Tippelt, B., Schulz, C., Röhl, F.W., Feneberg, A., Seidensticker, R., Arend, J. and Malfertheiner, P. (2015) Malnutrition Is a Prognostic Factor in Patients with Hepatocellular Carcinoma (HCC). Clinical Nutrition (Edinburgh, Scotland), 34, 1122-1127. https://doi.org/10.1016/j.clnu.2014.11.007
|
[37]
|
Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Chiou, Y.Y., Huang, Y.H., Lee, F.Y., Lin, H.C., Hou, M.C. and Huo, T.I. (2017) ALBI and PALBI Grade Predict Survival for HCC across Treatment Modalities and BCLC Stages in the MELD Era. Journal of Gastroenterology and Hepatology, 32, 879-886. https://doi.org/10.1111/jgh.13608
|
[38]
|
Chen, H., Hu, N., Chang, P., Kang, T., Han, S., Lu, Y. and Li, M. (2017) Modified Glasgow Prognostic Score Might Be a Prognostic Factor for Hepatocellular Carcinoma: A Meta-Analysis. Panminerva Medica, 59, 302-307. https://doi.org/10.23736/S0031-0808.16.03236-5
|
[39]
|
Casadei-Gardini, A., Dadduzio, V., Rovesti, G., Cabibbo, G., Vukotic, R., Rizzato, M.D., Orsi, G., Rossi, M., Guarneri, V., Lonardi, S., D’agostino, D., Celsa, C., Andreone, P., Zagonel, V., Scartozzi, M., Cascinu, S. and Cucchetti, A. (2020) Utility of Neutrophil-to-Lymphocyte Ratio to Identify Long-Term Survivors among HCC Patients Treated with Sorafenib. Medicine, 99, e19958. https://doi.org/10.1097/MD.0000000000019958
|